Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study
-
Published:2024-05
Issue:3
Volume:24
Page:431-436
-
ISSN:1424-3903
-
Container-title:Pancreatology
-
language:en
-
Short-container-title:Pancreatology
Author:
Suto HironobuORCID,
Matsukawa Hiroyuki,
Fuke Takuro,
Nagao Mina,
Ando Yasuhisa,
Oshima Minoru,
Yamana Hiroki,
Kamada Hideki,
Kobara HidekiORCID,
Okuyama Hiroyuki,
Kumamoto Kensuke,
Okano KeiichiORCID
Reference32 articles.
1. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer;Neoptolemos;N Engl J Med,2004
2. Unno M, Motoi T, Matsuyama Y, Satoi S, Matsumoto I, Aosasa S, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). In: 2019 ASCO annual meeting. Chicago, IL.
3. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial;Oettle;JAMA,2007
4. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial;Oettle;JAMA,2013
5. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01);Uesaka;Lancet,2016